Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated Advanced Non-small Cell Lung Cancer
B Li, J Xue, Y Wang, Z Huang, N Liang… - Zhongguo fei ai za zhi …, 2022 - europepmc.org
肺癌是最常见, 致死率最高的肿瘤性疾病之一, 使用表皮生长因子受体酪氨酸激酶抑制剂
(epidermal growth factor receptor tyrosine kinase inhibitor, EGRF-TKI) 已经成为 EGFR …
(epidermal growth factor receptor tyrosine kinase inhibitor, EGRF-TKI) 已经成为 EGFR …
[HTML][HTML] Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
N Iwamoto, YH Kim, S Iwatsubo… - Journal of Thoracic …, 2022 - ncbi.nlm.nih.gov
TKI and vascular endothelial growth factor (VEGF) or VEGF-receptor (VEGFR) inhibitors are
promising. In the RELAY study, although the OS data are still immature, progression-free …
promising. In the RELAY study, although the OS data are still immature, progression-free …
Comparison of the efficacy and safety of icotinib monotherapy and combined therapy of icotinib and vinorelbine as first-line treatment for advanced lung …
H Hu, J Yu, D Lin, H Xu - 2023 - researchsquare.com
This investigation compares the safety and therapeutic efficiency of icotinib monotherapy
and icotinib+ vinorelbine combination therapy against non-small cell lung cancer (NSCLC) …
and icotinib+ vinorelbine combination therapy against non-small cell lung cancer (NSCLC) …
Effect of Smoking Status on the Efficacy of EGFR-TKI Plus Anti-Angiogenic Agent in Advanced EGFR-Mutant NSCLC
XD Jiao, Y Wu, Y Wang, Y Ling, K Liu, YS Zang - papers.ssrn.com
The types of epidermal growth factor receptor (EGFR)–mutant non–small-cell lung cancer
(NSCLC) patients who could obtain significant clinical benefit from the dual inhibition of …
(NSCLC) patients who could obtain significant clinical benefit from the dual inhibition of …
[PDF][PDF] 肺癌患者におけるEGFR 遺伝子変異検査の手引き
日本肺癌学会， 西野和美， 西尾和人， 畑中豊， 池田貞勝… - 2016 - haigan.gr.jp
第 1.0 版 2009 年 3 月 6 日第 1.7 版 2009 年 5 月 11 日第 2.0 版 2014 年 2 月 11 日第 2.1 版
2014 年 4 月 14 日第 3.0 版 2016 年 11 月 2 日第 3.05 版 2016 年 12 月 1 日第 4.0 版 2018 年 …
2014 年 4 月 14 日第 3.0 版 2016 年 11 月 2 日第 3.05 版 2016 年 12 月 1 日第 4.0 版 2018 年 …